PBYI
Price
$3.00
Change
-$0.03 (-0.99%)
Updated
Apr 24, 04:59 PM (EDT)
Capitalization
149.33M
6 days until earnings call
VRCA
Price
$0.47
Change
+$0.01 (+2.17%)
Updated
Apr 24 closing price
Capitalization
43.13M
12 days until earnings call
Ad is loading...

PBYI vs VRCA

Header iconPBYI vs VRCA Comparison
Open Charts PBYI vs VRCABanner chart's image
Puma Biotechnology
Price$3.00
Change-$0.03 (-0.99%)
Volume$1.58K
Capitalization149.33M
Verrica Pharmaceuticals
Price$0.47
Change+$0.01 (+2.17%)
Volume$183.48K
Capitalization43.13M
PBYI vs VRCA Comparison Chart
Loading...
PBYI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRCA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
PBYI vs. VRCA commentary
Apr 25, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PBYI is a StrongBuy and VRCA is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 25, 2025
Stock price -- (PBYI: $3.01 vs. VRCA: $0.47)
Brand notoriety: PBYI and VRCA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PBYI: 54% vs. VRCA: 41%
Market capitalization -- PBYI: $149.33M vs. VRCA: $43.13M
PBYI [@Biotechnology] is valued at $149.33M. VRCA’s [@Biotechnology] market capitalization is $43.13M. The market cap for tickers in the [@Biotechnology] industry ranges from $275.91B to $0. The average market capitalization across the [@Biotechnology] industry is $2.09B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PBYI’s FA Score shows that 1 FA rating(s) are green whileVRCA’s FA Score has 0 green FA rating(s).

  • PBYI’s FA Score: 1 green, 4 red.
  • VRCA’s FA Score: 0 green, 5 red.
According to our system of comparison, PBYI is a better buy in the long-term than VRCA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PBYI’s TA Score shows that 4 TA indicator(s) are bullish while VRCA’s TA Score has 6 bullish TA indicator(s).

  • PBYI’s TA Score: 4 bullish, 5 bearish.
  • VRCA’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, VRCA is a better buy in the short-term than PBYI.

Price Growth

PBYI (@Biotechnology) experienced а +5.24% price change this week, while VRCA (@Biotechnology) price change was -4.89% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +8.06%. For the same industry, the average monthly price growth was -5.30%, and the average quarterly price growth was -11.62%.

Reported Earning Dates

PBYI is expected to report earnings on Jul 31, 2025.

VRCA is expected to report earnings on Aug 12, 2025.

Industries' Descriptions

@Biotechnology (+8.06% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PBYI($149M) has a higher market cap than VRCA($43.1M). PBYI YTD gains are higher at: -1.311 vs. VRCA (-33.357). PBYI has higher annual earnings (EBITDA): 48.1M vs. VRCA (-65.9M). PBYI has more cash in the bank: 101M vs. VRCA (46.3M). VRCA has less debt than PBYI: VRCA (45.9M) vs PBYI (74.1M). PBYI has higher revenues than VRCA: PBYI (230M) vs VRCA (7.57M).
PBYIVRCAPBYI / VRCA
Capitalization149M43.1M346%
EBITDA48.1M-65.9M-73%
Gain YTD-1.311-33.3574%
P/E Ratio4.87N/A-
Revenue230M7.57M3,040%
Total Cash101M46.3M218%
Total Debt74.1M45.9M161%
FUNDAMENTALS RATINGS
PBYI vs VRCA: Fundamental Ratings
PBYI
VRCA
OUTLOOK RATING
1..100
116
VALUATION
overvalued / fair valued / undervalued
1..100
43
Fair valued
96
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
24100
PRICE GROWTH RATING
1..100
6194
P/E GROWTH RATING
1..100
96100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PBYI's Valuation (43) in the Biotechnology industry is somewhat better than the same rating for VRCA (96) in the Pharmaceuticals Major industry. This means that PBYI’s stock grew somewhat faster than VRCA’s over the last 12 months.

PBYI's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as VRCA (100) in the Pharmaceuticals Major industry. This means that PBYI’s stock grew similarly to VRCA’s over the last 12 months.

PBYI's SMR Rating (24) in the Biotechnology industry is significantly better than the same rating for VRCA (100) in the Pharmaceuticals Major industry. This means that PBYI’s stock grew significantly faster than VRCA’s over the last 12 months.

PBYI's Price Growth Rating (61) in the Biotechnology industry is somewhat better than the same rating for VRCA (94) in the Pharmaceuticals Major industry. This means that PBYI’s stock grew somewhat faster than VRCA’s over the last 12 months.

PBYI's P/E Growth Rating (96) in the Biotechnology industry is in the same range as VRCA (100) in the Pharmaceuticals Major industry. This means that PBYI’s stock grew similarly to VRCA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PBYIVRCA
RSI
ODDS (%)
N/A
Bullish Trend 1 day ago
87%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 1 day ago
85%
Momentum
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 1 day ago
79%
MACD
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 1 day ago
90%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 1 day ago
90%
Advances
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 11 days ago
87%
Declines
ODDS (%)
Bearish Trend 8 days ago
86%
Bearish Trend 9 days ago
89%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 1 day ago
80%
Aroon
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 1 day ago
90%
View a ticker or compare two or three
Ad is loading...
PBYI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRCA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
VCIG4.730.73
+18.25%
VCI Global Limited
OLED125.456.97
+5.88%
Universal Display Corp
ETWO2.130.05
+2.40%
E2open Parent Holdings
COOK1.49-0.01
-0.67%
Traeger
MNST58.59-0.50
-0.85%
Monster Beverage Corp

PBYI and

Correlation & Price change

A.I.dvisor indicates that over the last year, PBYI has been loosely correlated with RGNX. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if PBYI jumps, then RGNX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PBYI
1D Price
Change %
PBYI100%
-0.66%
RGNX - PBYI
37%
Loosely correlated
+3.72%
COGT - PBYI
35%
Loosely correlated
+0.89%
MDGL - PBYI
34%
Loosely correlated
+3.61%
AURA - PBYI
34%
Loosely correlated
-4.17%
RARE - PBYI
34%
Loosely correlated
+0.88%
More